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Wakefulness: An eye-opening perspective on orexin neurons
T.E. Scammell
Orexin-containing neurons regulate wakefulness, and
loss of orexin produces narcolepsy. Recent studies of
mice lacking orexin neurons have shown that these
cells also play essential roles in the control of feeding
and energy balance.
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Predation, starvation and hypothermia are the leading causes
of death for mice living in the wild. With little body fat,
mice and many other animals often need to spend much of
their active period watching for predators, searching for food
and staying warm. This requires the coordination of systems
that regulate feeding, body temperature and autonomic
functions with those that govern the timing of alertness.
Until recently, little was known about the control of these
functions, but recent observations on the role of hypothala-
mic neurons containing orexins have demonstrated how one
type of neuron may influence many physiologic functions. 
Orexin-A and orexin–B — also known as hypocretin-1 and
hypocretin-2 — are small neuropeptides produced by
neurons in the lateral hypothalamus [1,2]. Orexin-containing
neurons heavily innervate brain regions involved in the
control of wakefulness, appetite, thermoregulation and
autonomic control [3,4], and orexins have excitatory effects
on post-synaptic neurons [2,5] (Figure 1). Orexin neurons
are predominantly active during wakefulness [6], and injec-
tion of orexin-A into the lateral ventricles increases wake-
fulness, food intake, body temperature and sympathetic
activity [1,5,7,8].
Although the orexins mediate many functions, narcolepsy
is the most striking abnormality in animals with abnormal
orexin signaling. Orexin knockout mice and dogs with
orexin receptor mutations have many signs of narcolepsy
and have provided key insights into the neurobiology of
narcolepsy in humans [4,9]. People with narcolepsy have
chronic, sometimes severe daytime sleepiness that typi-
cally begins in young adulthood and is often accompanied
by episodic intrusions of rapid eye movement (REM)
sleep-like phenomena into wakefulness. Vivid dreams and
muscular paralysis occur during REM sleep, and people
with narcolepsy may have dream-like hallucinations or
sudden episodes of muscular paralysis or weakness known
as cataplexy.
Orexin signaling is probably abnormal in people with
narcolepsy because they have a marked reduction in the
number of hypothalamic orexin neurons [10,11], and the
concentration of orexin in their cerebrospinal fluid is
usually very low [12]. Unlike the mouse and dog models,
human narcoleptics rarely have mutations in the genes
coding for orexin or its receptors [10]. Most likely an
inflammatory, possibly autoimmune, process kills the orexin
neurons in young adulthood. Whatever the cause, the loss
of orexin from the brains of narcoleptics clearly indicates
that impaired orexin signaling can cause narcolepsy in
humans as well as in animal models.
While peptide knockout animals such as the orexin knock-
out mice are helpful in understanding the role of specific
peptides, this approach cannot fully define the function of
specific neuronal populations. To produce an animal model
that closely resembles human narcolepsy, Hara and col-
leagues [13] recently produced mice with an acquired loss
of orexin neurons. These mice contain a transgene in
which the human orexin promoter drives the expression of
a mutant form of ataxin-3, a protein that induces apoptosis
in neurons. These mice lose 90% of their orexin neurons
by 8 weeks of age, and at 15 weeks nearly all orexin neurons
are gone. This neuronal death is specific to the orexin
neurons, with no apparent loss of nearby neurons such as
those that produce melanin concentrating hormone or neu-
ropeptide Y. As seen in orexin peptide knockout mice,
adult orexin/ataxin-3 mice have a behavioral phenotype
that strongly resembles narcolepsy. The organization of
sleep/wake behavior is disrupted, with briefer episodes of
wakefulness that may be the functional expression of
chronic sleepiness. These mice also have little diurnal vari-
ation in the amount of REM sleep, abrupt transitions into
REM sleep, and sudden behavioral arrests in which they
may wobble or collapse, similar to cataplexy in humans.
How might orexin loss disrupt sleep/wake behavior?
Wakefulness is promoted by aminergic brain regions such
as the locus coeruleus which diffusely activate the cortex,
and by cholinergic regions that produce thalamic activation,
allowing flow of information to and from the cortex.
Orexin-containing fibers innervate all these wake-promot-
ing regions, and orexin increases the firing rates of aminer-
gic neurons in vitro [5]. Impaired orexin signaling may
produce insufficient activation of these wake-promoting
areas, resulting in poorly sustained wakefulness.
The dysregulation of REM sleep may be caused by a
similar mechanism. Mice normally have 2–3 times as much
REM sleep during the day than at night, and they only
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enter REM sleep after 8–10 minutes of non-REM sleep.
However, both orexin knockout and orexin/ataxin-3 mice
exhibit less diurnal variation in REM sleep, and they
often enter REM sleep rapidly, sometimes even switching
abruptly from wakefulness into REM sleep. People with
narcolepsy also can quickly enter REM sleep at any time
of day. REM-promoting neurons in the pons are normally
inhibited by aminergic neurons, and in the absence of
orexin, aminergic activity may be lower and REM sleep
may occur more readily. A simple disinhibition of REM
sleep seems unlikely, however, because both strains of nar-
coleptic mice have normal amounts of REM sleep each
day. REM sleep is strongly influenced by circadian rhythms
[14], and the nearly equal distribution of REM sleep across
the light and dark periods in orexin knockout mice sug-
gests that circadian factors may influence sleep/wake behav-
ior through the orexin neurons. Thus, a loss of orexin may
disrupt the circadian timing of REM sleep, and this impaired
timing would allow REM sleep to occur at any time.
Beyond these abnormalities of behavioral state control, the
orexin/ataxin-3 mice also convincingly demonstrate that
the orexin neurons influence feeding and energy hom-
eostasis. Mice simply lacking the orexin peptides eat roughly
normal amounts, but have a tendency to become obese
when fed a high fat diet [15]. In contrast, orexin/ataxin-3
mice become obese even on a normal diet [13]. By 20 weeks
of age, they weigh about 40% more than wild-type litter-
mates, but remarkably, they eat less, especially during the
night when most feeding occurs. 
How might loss of orexin neurons produce hypophagia and
obesity?
The phenotypic differences between orexin knockout mice
and orexin/ataxin-3 mice may reflect the different back-
ground strains in these two models, or it may be that an
acquired loss of orexin in young adulthood has different
effects than seen with constitutive loss. However, the orexin
neurons contain other neurotransmitters in addition to
orexin. Chou and colleagues [16] have demonstrated that
essentially all orexin neurons contain dynorphin, and loss
of the orexin neurons results in a complete loss of dynor-
phin mRNA in the lateral hypothalamus. Because injec-
tion of dynorphin into the hypothalamus promotes feeding,
loss of this dynorphin may contribute to the decreased
food intake of the orexin/ataxin-3 mice. 
A decrease in energy expenditure may explain why loss of
orexin neurons produces obesity. Decreased muscular activ-
ity may provide a partial explanation, because orexin/ataxin-3
mice have less locomotor activity than normal at night [13].
Basal metabolic rate is strongly influenced by sympathetic
Figure 1
Pathways through which orexin neurons
control many behaviors. Orexin increases the
activity of aminergic arousal regions including
the locus coeruleus (LC) and raphe nuclei that
then increase wakefulness and suppress REM
sleep. Neuroendocrine responses such as
increases in cortisol are mediated by
projections that influence pituitary function.
Orexin neurons may promote feeding through
projections to the arcuate nucleus (Arc) and
ventromedial hypothalamic nucleus (VMH).
Orexin neurons may increase the activity of the
sympathetic nervous system through
projections to the ventrolateral medulla (VLM)
and spinal cord.
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activity, and injection of orexin into the lateral ventricles
increases blood pressure, heart rate and plasma epineph-
rine, most likely through activation of autonomic regulatory
brain regions and increases in sympathetic activity [8,17,18].
The thermogenic effects of orexin might be due to sympa-
thetically mediated increases in brown fat heat production.
Thus, even at rest, orexin/ataxin-3 mice may have low sym-
pathetic tone, burn fewer calories and become obese. 
Do people with a loss of orexin neurons have abnormali-
ties in feeding and metabolism? People with narcolepsy
may eat less [19] but are often mildly overweight [20].
While narcoleptics have no gross abnormalities in sympa-
thetic activity, these observations suggest that their basal
metabolic rate or level of physical activity may be low, and
several studies are underway to define more clearly these
metabolic abnormalities. 
The orexin/ataxin-3 mice provide a new perspective into
the multifunctional nature of the orexin neurons. Loss of
orexin clearly produces narcolepsy, but loss of the orexin
neurons also produces hypophagia and obesity. These
neurons are thus critically positioned to coordinate feeding
and the control of autonomic activity and metabolic rate
with the regulation of sleep/wake behavior. Integration of
these behaviors may help ensure that animals are metabol-
ically active and alert while seeking food at the correct
time of day. 
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